Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.43 |
| ▸ | ADH1A | P07327 | 4/20 | 0.43 |
| ▸ | ADH1C | P00326 | 3/20 | 0.40 |
| ▸ | ADH7 | P40394 | 2/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6247547 | 0.88 | ADH1B (0.52) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL13451631 | 0.83 | TEAD1 (0.33) | EPHX1EPHX2 | |
| SCHEMBL771167 | 0.83 | EPHX2 (0.46) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL772153 | 0.80 | EPHX1 (0.41) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL29134343 | 0.80 | THRB (0.42) | EPHX1THRBATML3MBTL1EPHX2 | |
| SCHEMBL29134344 | 0.80 | THRB (0.42) | EPHX1THRBATML3MBTL1EPHX2 | |
| SCHEMBL7560672 | 0.79 | ADH1B (0.42) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL671290 | 0.77 | THRB (0.51) | EPHX1THRBATML3MBTL1EPHX2 | |
| SCHEMBL4122335 | 0.77 | THRB (0.47) | EPHX1THRBATML3MBTL1EPHX2 | |
| SCHEMBL4112587 | 0.77 | THRB (0.51) | EPHX1THRBATML3MBTL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1828121-A2 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064336-A2 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | AOC3, AOC2, TPH2 | ADH1B 1487/4885ADH1A 548/4885ADH1C 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.